Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

Executive Summary

• Satellos Bioscience Inc. filed a preliminary prospectus supplement to its short‑form base shelf prospectus in preparation for a public offering of common shares (or pre‑funded warrants).
• The company also applied to list its common shares on the Nasdaq Global Market under the ticker “MSLE,” with trading expected to commence after pricing of the offering.
• Net proceeds are intended to fund ongoing R&D, working capital and general corporate purposes, including advancement of SAT‑3248 (SAT‑3247) clinical programs.

Key Details

• Prospectus Filing: Preliminary supplement filed with securities regulators in BC, Alberta, Ontario and with the U.S. SEC (Form F‑10). Base prospectus dated October 29 2025 will be accessible on SEDAR+ within two business days.
• Offering Structure: Proposed public offering of common shares or pre‑funded warrants; underwriters granted a 30‑day option to purchase up to an additional 15% of the offered securities (over‑allotment).
• Pricing & Size: Final terms, including price per share/warrant and total size, will be determined at pricing; no specific amount disclosed.
• Use of Proceeds: Funding for ongoing research and development activities, working capital, general corporate purposes, and advancement of SAT‑3247 through Phase 2–Phase 3 trials or other indications, plus investment in additional discovery/pre‑clinical programs.
• Underwriters/Managers: Joint‑book running managers – Leerink Partners, Guggenheim Securities, Oppenheimer & Co.; co‑manager – Bloom Burton.
• Nasdaq Listing Application: Application submitted to list common shares on Nasdaq under ticker “MSLE”; trading expected after pricing and upon meeting listing requirements.
• Closing Conditions: Offering subject to customary closing conditions, including approvals from Toronto Stock Exchange and Nasdaq.

Notable Quotes

(No executive quotes were included in the release.)